Mr. Brent Zettl reports

ZYUS LIFE SCIENCES ANNOUNCES ACTIVATION OF TWO ADDITIONAL CLINICAL SITES IN PHASE 2A UTOPIA-1 CANCER PAIN TRIAL

Zyus Life Sciences Corp. has activated two additional clinical sites in its phase 2a Utopia-1 (Unique Treatment of Oncology Pain in Advanced Cancer) trial. The addition of CancerCare Manitoba (CCMB) and the Research Institute of the McGill University Health Centre, along with the Centre Hospitalier de l'Universite de Montreal (CHUM), expands the phase 2a Utopia-1 trial to three active clinical sites across Canada.

Utopia-1 is a single-arm, proof-of-concept study designed to evaluate the safety and preliminary analgesic efficacy of Trichomylin soft-gel capsules in patients with advanced cancer and moderate to severe cancer-related pain. With three active sites, the trial is positioned to broaden diversity of trial participants and accelerate patient enrolment in the phase 2a Utopia-1 trial evaluating Trichomylin soft-gel capsules.

"Expanding the Utopia-1 trial to three clinical sites marks a meaningful step forward in our mission to deliver safer, scientifically validated alternatives that have the potential to improve patient outcomes," said Brent Zettl, president and chief executive officer of Zyus Life Sciences. "The activation of these two additional clinical sites strengthens our clinical development program and advances our path toward generating preliminary efficacy and safety data needed to progress Trichomylin soft-gel capsules into later-stage trials."

About Zyus Life Sciences Corp.

Zyus is a life sciences company focused on the development and commercialization of novel cannabinoid-based pharmaceutical drug candidates for pain management. Through rigorous scientific exploration and clinical research, Zyus aims to secure intellectual property protection, safeguarding its innovative therapies and bolstering shareholder value. Zyus's unwavering commitment extends to obtaining regulatory approval of non-opioid-based pharmaceutical solutions, in pursuit of transformational impact on patients' lives.

We seek Safe Harbor.